Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Ventyx Biosciences (Nasdaq: VTYX), a clinical-stage biopharmaceutical company specializing in innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.
The virtual event is scheduled for Wednesday, February 12, 2025, from 2:40-3:10 PM ET. The company will provide a presentation, which will be accessible via webcast through the Investors and News section of Ventyx's website at www.ventyxbio.com. A replay of the presentation will remain available on the website for ninety days following the event.
Ventyx Biosciences (Nasdaq: VTYX), un'azienda biofarmaceutica in fase clinica specializzata in terapie orali innovative per malattie autoimmuni, infiammatorie e neurodegenerative, ha annunciato la sua partecipazione alla prossima 35ª Conferenza Annuale sulle Scienze della Salute di Oppenheimer.
L'evento virtuale è programmato per mercoledì 12 febbraio 2025, dalle 14:40 alle 15:10 ET. L'azienda fornirà una presentazione, che sarà accessibile tramite webcast nella sezione Investitori e Notizie del sito web di Ventyx all'indirizzo www.ventyxbio.com. Una registrazione della presentazione sarà disponibile sul sito per novanta giorni dopo l'evento.
Ventyx Biosciences (Nasdaq: VTYX), una compañía biofarmacéutica en etapa clínica especializada en terapias orales innovadoras para enfermedades autoinmunes, inflamatorias y neurodegenerativas, ha anunciado su participación en la próxima 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer.
El evento virtual está programado para miércoles, 12 de febrero de 2025, de 2:40 a 3:10 PM ET. La compañía ofrecerá una presentación, que estará accesible a través de un webcast en la sección de Inversores y Noticias del sitio web de Ventyx en www.ventyxbio.com. Una repetición de la presentación estará disponible en el sitio durante noventa días después del evento.
벤티히스 바이오사이언스(Ventyx Biosciences, Nasdaq: VTYX)는 자가 면역, 염증, 신경퇴행성 질환을 위한 혁신적인 경구 치료제를 전문으로 하는 임상 단계의 생물 제약 회사로, 오펜하이머 제35회 연례 헬스케어 생명과학 컨퍼런스에 참여한다고 발표했습니다.
이번 가상 행사는 2025년 2월 12일 수요일, 오후 2시 40분부터 3시 10분(동부 표준시)로 예정되어 있습니다. 회사는 발표를 진행할 예정이며, 벤티히스의 웹사이트 www.ventyxbio.com의 투자자 및 뉴스 섹션을 통해 웹캐스트 형식으로 접근할 수 있을 것입니다. 발표의 재생은 행사 후 90일간 웹사이트에서 이용할 수 있습니다.
Ventyx Biosciences (Nasdaq: VTYX), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies orales innovantes pour les maladies auto-immunes, inflammatoires et neurodégénératives, a annoncé sa participation à la prochaine 35e Conférence Annuelle des Sciences de la Santé d'Oppenheimer.
L'événement virtuel est prévu pour mercredi 12 février 2025, de 14h40 à 15h10 ET. L'entreprise fera une présentation, qui sera accessible via webcast dans la section Investisseurs et Actualités du site web de Ventyx à www.ventyxbio.com. Un enregistrement de la présentation sera disponible sur le site pendant quatre-vingt-dix jours après l'événement.
Ventyx Biosciences (Nasdaq: VTYX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf innovative orale Therapien für autoimmune, entzündliche und neurodegenerative Erkrankungen spezialisiert hat, hat seine Teilnahme an der bevorstehenden 35. Jahrestagung der Oppenheimer Healthcare Life Sciences Conference bekannt gegeben.
Die virtuelle Veranstaltung ist für Mittwoch, den 12. Februar 2025, von 14:40 bis 15:10 Uhr ET geplant. Das Unternehmen wird eine Präsentation geben, die über einen Webcast in der Rubrik Investoren und Neuigkeiten auf der Website von Ventyx unter www.ventyxbio.com zugänglich sein wird. Eine Wiederholung der Präsentation wird für neunzig Tage nach der Veranstaltung auf der Website verfügbar sein.
- None.
- None.
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.
- Event: Oppenheimer 35th Annual Healthcare Life Sciences Conference
Location: Virtual
Date: Wednesday, February 12, 2025
Time: 2:40-3:10 PM ET
A webcast of the presentation will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of the event for ninety days.
About Ventyx Biosciences
Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Our expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drugs through clinical trials. Our lead portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase 2 development for neurodegenerative and cardiometabolic diseases. Our inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase 2 clinical trials.
Investor Relations Contact:
Joyce Allaire
Managing Director
LifeSci Advisors
IR@ventyxbio.com
FAQ
When is Ventyx Biosciences (VTYX) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors access the VTYX presentation at the Oppenheimer Conference?
How long will the VTYX Oppenheimer Conference presentation replay be available?
What therapeutic areas does Ventyx Biosciences (VTYX) focus on?
